Asset Details
Do you wish to reserve the book?
CD44/HA signaling mediates acquired resistance to a PI3Kα inhibitor
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CD44/HA signaling mediates acquired resistance to a PI3Kα inhibitor
Do you wish to request the book?
CD44/HA signaling mediates acquired resistance to a PI3Kα inhibitor
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CD44/HA signaling mediates acquired resistance to a PI3Kα inhibitor
2020
Overview
Most luminal breast carcinomas (BrCas) bearing PIK3CA mutations initially respond to phosphoinositide-3-kinase (PI3K)-α inhibitors, but many eventually become resistant. The underlying mechanisms of this resistance remain obscure. In this work, we showed that a CD44
high
state due to aberrant isoform splicing was acquired from adaptive resistance to a PI3Kα inhibitor (BLY719) in luminal BrCas. Notably, the expression of CD44 was positively correlated with estrogen receptor (ER) activity in PIK3CA-mutant breast cancers, and ER-dependent transcription upon PI3Kα pathway inhibition was in turn mediated by CD44. Furthermore, the interaction of CD44 with the ligand hyaluronan (HA) initiated the Src-ERK signaling cascade, which subsequently maintained AKT and mTOR activity in the presence of a PI3Kα inhibitor. Activation of this pathway was prevented by disruption of the CD44/HA interaction, which in turn restored sensitivity to BLY719. Our results revealed that an ER-CD44-HA signaling circuit that mediates robust compensatory activation of the Src-ERK signaling cascade may contribute to the development of acquired resistance to PI3Kα inhibitors. This study provides new insight into the mechanism of adaptive resistance to PI3Kα inhibition therapy.
Publisher
Nature Publishing Group UK
Subject
/ 13/31
/ 13/51
/ 38/39
/ 38/77
/ 38/79
/ 64/60
/ 82/1
/ 82/80
/ 96/63
/ Biomedical and Life Sciences
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - pathology
/ Class I Phosphatidylinositol 3-Kinases - drug effects
/ Class I Phosphatidylinositol 3-Kinases - metabolism
/ Drug Resistance, Neoplasm - drug effects
/ Humans
/ Hyaluronan Receptors - drug effects
/ Hyaluronan Receptors - metabolism
/ Phosphatidylinositol 3-Kinases - drug effects
/ Phosphatidylinositol 3-Kinases - metabolism
/ Phosphoinositide-3 Kinase Inhibitors - pharmacology
/ Signal Transduction - drug effects
